<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Nonemergent treatment of hypertension in children and adolescents</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Nonemergent treatment of hypertension in children and adolescents</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Nonemergent treatment of hypertension in children and adolescents</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">F Bruder Stapleton, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 01, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>It has become clear that hypertension (HTN) begins in childhood and adolescence and that it contributes to the early development of cardiovascular disease (CVD). In hypertensive adults, multiple randomized trials have shown that reduction of blood pressure (BP) by antihypertensive therapy reduces cardiovascular morbidity and mortality. Based upon these observations, identifying children with HTN and successfully treating their HTN should have an important impact on long-term outcomes of CVD. (See  <a class="medical medical_review" href="/z/d/html/3861.html" rel="external">"Goal blood pressure in adults with hypertension"</a>.)</p><p>Issues related to the ambulatory (outpatient) treatment of persistent HTN in children and adolescents will be reviewed here. The epidemiology, etiology, diagnosis, and evaluation of HTN are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6111.html" rel="external">"Epidemiology, risk factors, and etiology of hypertension in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/6087.html" rel="external">"Definition and diagnosis of hypertension in children and adolescents"</a> and  <a class="medical medical_review" href="/z/d/html/6088.html" rel="external">"Evaluation of hypertension in children and adolescents"</a>.)</p><p>The treatment of hypertensive emergencies and urgencies in children is also presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6468.html" rel="external">"Initial management of hypertensive emergencies and urgencies in children"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">DEFINITIONS</span><span class="headingEndMark"> — </span>In children, definitions based upon the 2017 American <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fpediatrics.aappublications.org%2Fcontent%2Fearly%2F2017%2F08%2F21%2Fpeds.2017-1904.full&amp;token=cg%2FUCQM33sNQy%2BqXTCKCRj231mK0UhmBjFaG%2FFus86bpXmQ0ED%2BDx48mhvHjhlvlcKiOK4XFwdLpYMoeW7y0%2F%2BPVC%2FdafYbo15HpJVqqfi6m3Y3dL692YBN%2B9tlL9%2B9R&amp;TOPIC_ID=6131" target="_blank">Academy of Pediatrics (AAP) guidelines</a> for screening and managing high blood pressure for children and adolescents for high blood pressure (BP) in children and adolescents are used to classify BP measurements for two different age groups in the United States  (<a class="graphic graphic_table graphicRef114574" href="/z/d/graphic/114574.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]. BP percentiles are based upon sex, age, and height  (<a class="graphic graphic_table graphicRef63856" href="/z/d/graphic/63856.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef52646" href="/z/d/graphic/52646.html" rel="external">table 3</a>). (See  <a class="medical medical_review" href="/z/d/html/6087.html" rel="external">"Definition and diagnosis of hypertension in children and adolescents", section on 'Definitions'</a>.)</p><p>Childhood HTN is also divided into two categories depending upon whether or not an underlying cause can be identified  (<a class="graphic graphic_table graphicRef101809" href="/z/d/graphic/101809.html" rel="external">table 4</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Primary HTN – No identifiable cause is found.</p><p class="bulletIndent1"><span class="glyph">●</span>Secondary HTN – An underlying cause is identified.</p><p></p><p class="headingAnchor" id="H3"><span class="h1">RATIONALE FOR INTERVENTION</span><span class="headingEndMark"> — </span>Pediatric hypertension is associated with an increased long-term risk for CVD and progression of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) in adults. </p><p class="headingAnchor" id="H3936157759"><span class="h2">Cardiovascular disease</span><span class="headingEndMark"> — </span>Although there is no direct evidence that initiating therapy to lower blood pressure (BP) in children and adolescents with persistent HTN lowers the risk of subsequent CVD, there is strong indirect evidence that HTN in childhood and adolescence contributes to premature atherosclerosis and increases the risk of CVD [<a href="#rid1">1-3</a>]. These data suggest that lowering the BP in hypertensive children would reduce the risk of accelerated atherosclerosis and, subsequently, premature CVD in adults.</p><p class="bulletIndent1"><span class="glyph">●</span>HTN is a well-established risk factor for CVD in adults, which appears to be true for persistent childhood HTN. Children and adolescents who are hypertensive or have prehypertension are more likely to be hypertensive as adults. An Israeli study of 16 to 19 year old adolescents with persistent HTN reported an increased risk of cardiovascular death in midlife after adjusting for confounding factors [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/6087.html" rel="external">"Definition and diagnosis of hypertension in children and adolescents", section on 'Tracking'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HTN is a risk factor for accelerated atherosclerosis in children and young adults. (See  <a class="medical medical_review" href="/z/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood", section on 'Hypertension'</a> and  <a class="medical medical_review" href="/z/d/html/5781.html" rel="external">"Overview of risk factors for development of atherosclerosis and early cardiovascular disease in childhood", section on 'Atherosclerotic changes in childhood'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In children and adolescents, noninvasive methods of assessment of vascular changes related to atherosclerosis demonstrate an association of higher BP with predictors of CVD including arterial stiffness measured by pulse wave velocity [<a href="#rid5">5,6</a>], arterial calcification [<a href="#rid7">7,8</a>], and carotid intima media thickness (CIMT) evaluated by computed tomography (CT) or carotid ultrasound [<a href="#rid8">8-11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among children and adolescents with borderline or established primary HTN, left ventricular hypertrophy (LVH) has been reported in up to 40 to 45 percent of cases [<a href="#rid12">12,13</a>]. LVH increases with greater body mass index (BMI). Longitudinal data from the Bogalusa Heart study have shown that elevated childhood BP and BMI were associated with an increased risk of LVH in adulthood [<a href="#rid14">14-16</a>]. In adults, LVH is a known risk factor for CVD.</p><p></p><p class="bulletIndent1">Limited pediatric data also show that antihypertensive therapy is associated with LVH regression [<a href="#rid17">17-21</a>]. In one study in children with primary and secondary HTN, the prevalence of LVH decreased from 42 percent to 11 percent after six months of treatment with <a class="drug drug_general" data-topicid="9851" href="/z/d/drug information/9851.html" rel="external">ramipril</a>, an angiotensin-converting enzyme (ACE) antihypertensive agent [<a href="#rid18">18</a>].</p><p></p><p class="headingAnchor" id="H3017949650"><span class="h2">Chronic kidney disease and end-stage kidney disease</span><span class="headingEndMark"> — </span>Untreated HTN is associated with progressive CKD. In children with chronic kidney disease (CKD), strict blood pressure control has been shown to slow the progression of kidney disease (see  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Hypertension'</a>). </p><p>In addition, it appears that essential HTN during late adolescence increases the risk of ESKD in adulthood. This was illustrated in a large retrospective study of almost 2.7 million healthy adolescents recruited to the Israeli army (age 16 to 19 years of age) that reported 2189 individuals (0.1 percent) developed ESKD (defined as requiring hemodialysis, peritoneal dialysis, or undergoing renal transplantation) at a median follow-up of 19.6 years (range 10.4 to 31.2) [<a href="#rid22">22</a>]. Individuals progressing to ESKD included 42 of the 7997 individuals (0.5 percent) diagnosed with HTN (defined as BP &gt;140/90) at the time of conscription. In a multivariable regression analysis, HTN at the time of conscription doubled the risk of ESKD (hazard ratio 1.98, 95% CI 1.42-2.77). Although the incidence of ESKD was low in this cohort, these results highlight the long-term potentially avoidable adverse effects of pediatric HTN on the development of ESKD.</p><p class="headingAnchor" id="H20"><span class="h1">MANAGEMENT APPROACH</span><span class="headingEndMark"> — </span>Treatment for chronic HTN includes both nonpharmacologic and pharmacologic interventions. Management decisions are dependent upon the severity of HTN, the underlying cause, and the presence of other cardiovascular disease (CVD) risk factors. Our management approach, which is consistent with the 2017 American Academy of Pediatrics (AAP) guidelines, is based upon defined target blood pressure (BP) thresholds and goals.</p><p class="headingAnchor" id="H21"><span class="h2">Target blood pressure goals</span><span class="headingEndMark"> — </span>In children and adolescents with high BP, the desired goal is to lower BP to an optimal level that reduces the risk of premature cardiovascular disease (CVD). However, no data are available to define these pediatric goals because long-term epidemiologic data linking cardiovascular events to childhood BP values are lacking. As a result, target BP goals have been determined by expert opinion. In the 2017 AAP guidelines, the target BP goal for children diagnosed with hypertension treated with nonpharmacologic and/or pharmacologic therapy is a reduction of systolic and diastolic BP below the 90<sup>th</sup> percentile or &lt;130/80 in adolescents (13 years or older) [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H3185374298"><span class="h3">Chronic kidney disease</span><span class="headingEndMark"> — </span>For children with chronic kidney disease (CKD), both the European Society of Hypertension (ESH) and AAP have more rigorous target goals because aggressive BP control has been shown to slow the progression of CKD. (See  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Hypertension'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>The ESH guidelines suggest:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For children with nonproteinuric CKD, 24-hour BP targeted goal is &lt;75<sup>th</sup> percentile</p><p class="bulletIndent2"><span class="glyph">•</span>For children with proteinuric CKD, 24-hour BP targeted goal is &lt;50<sup>th</sup> percentile</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The 2017 AAP guideline suggests a BP targeted goal of mean arterial BP &lt;50<sup>th</sup> percentile based on 24-hour ambulatory blood pressure monitoring (ABPM) [<a href="#rid1">1</a>]. </p><p></p><p class="headingAnchor" id="H22"><span class="h2">Who should be treated</span><span class="headingEndMark"> — </span>The initiation and aggressiveness of the therapy are generally based upon the severity of HTN, and the presence of end-organ damage, symptoms, or other CVD risk factors. Therapy includes nonpharmacologic and pharmacologic interventions and is focused upon achieving the previously discussed BP target goals. (See <a class="local">'Nonpharmacologic therapy'</a> below and <a class="local">'Choice of drug'</a> below.)</p><p>Our management approach is consistent with the 2017 AAP guidelines based on defined BP categories and the presence of other conditions associated with cardiovascular disease  (<a class="graphic graphic_table graphicRef114574" href="/z/d/graphic/114574.html" rel="external">table 1</a>) [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In <strong>children with elevated BP</strong>, nonpharmacologic therapy (eg, diet and exercise) is initiated to reduce their BP to below the 90<sup>th</sup> percentile or &lt;120/80 mmHg in adolescents who are 13 years or older. Although the 2017 AAP guidelines suggest a target goal &lt;130/80 mmHg, we prefer the lower goal of &lt;120/80 mmHg that is consistent with an upper limit of a normal BP for children and adolescents. (See <a class="local">'Nonpharmacologic therapy'</a> below and  <a class="medical medical_review" href="/z/d/html/6088.html" rel="external">"Evaluation of hypertension in children and adolescents", section on 'Laboratory evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In <strong>children with stage 1 primary hypertension</strong> (HTN) without evidence of end-organ damage or CVD risk factors, nonpharmacologic therapy is the initial intervention. If BP target goals are not met within four to six months after initial therapy (ie, BP below the 90<sup>th</sup> percentile), pharmacologic therapy is initiated. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In <strong>children with stage 1 HTN who are symptomatic or have evidence of end-organ damage</strong> (eg, left ventricular hypertrophy, retinal changes) or CVD risk factors, both nonpharmacologic and pharmacologic therapy are started. (See  <a class="medical medical_review" href="/z/d/html/3859.html" rel="external">"Ocular effects of hypertension"</a> and  <a class="medical medical_review" href="/z/d/html/6088.html" rel="external">"Evaluation of hypertension in children and adolescents", section on 'Detection of end-organ damage'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In <strong>children with stage 2 HTN</strong>, treatment with both nonpharmacologic and pharmacologic therapy is initiated. Patients with stage 2 HTN and neurologic symptoms including headache, mental status changes, and neurologic findings should be emergently evaluated and treated. (See  <a class="medical medical_review" href="/z/d/html/6468.html" rel="external">"Initial management of hypertensive emergencies and urgencies in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In <strong>children with secondary HTN</strong>, therapy should be directed to correcting the underlying cause, if possible. If the underlying cause cannot be corrected so that HTN is abolished, pharmacologic and nonpharmacologic therapy are initiated dependent on the elevation of BP. (See  <a class="medical medical_review" href="/z/d/html/6111.html" rel="external">"Epidemiology, risk factors, and etiology of hypertension in children and adolescents", section on 'Secondary hypertension'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with <strong>chronic kidney disease</strong> (CKD), both nonpharmacologic and pharmacologic therapy is provided for any child with elevated BP or HTN. (See  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Hypertension'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with <strong>diabetes mellitus</strong> (DM), both nonpharmacologic and pharmacologic therapy is provided for any child with any stage of HTN. (See  <a class="medical medical_review" href="/z/d/html/5826.html" rel="external">"Chronic complications and screening in children and adolescents with type 2 diabetes mellitus", section on 'Hypertension'</a> and  <a class="medical medical_review" href="/z/d/html/5818.html" rel="external">"Complications and screening in children and adolescents with type 1 diabetes mellitus", section on 'Hypertension'</a>.)</p><p></p><p class="headingAnchor" id="H2415815273"><span class="h2">General principles when starting pharmacologic therapy</span><span class="headingEndMark"> — </span>Based on strong indirect evidence of the association between pediatric hypertension and cardiovascular disease (CVD), antihypertensive drug therapy is used for children with persistently high BP, especially those with evidence of end-organ damage or other CVD risk factors and those with symptomatic hypertension. (See <a class="local">'Rationale for intervention'</a> above and <a class="local">'Who should be treated'</a> above.)</p><p>The principles of antihypertensive drug therapy are based upon the following step-wise approach [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>First-line drug therapy should combine efficacy with minimum side effects. Starting doses should be the lower end of the known effective dose  (<a class="graphic graphic_table graphicRef71466" href="/z/d/graphic/71466.html" rel="external">table 5</a>).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If the target BP is still not achieved, a second drug from a different class is added when the initial drug dose reaches the highest recommended level or if the patient begins to experience side effects from the initial drug. We typically use thiazide diuretic as the second agent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>To improve compliance, long-acting agents should be used whenever possible. For once-daily medications, we let the patient decide on morning versus evening intake as long as it is taken consistently around the same time.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonpharmacologic therapy is continued even if pharmacologic therapy is initiated.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ABPM is useful to assess response to therapy especially when clinic or home BP monitoring is insufficient to determine treatment effectiveness.</p><p></p><p class="headingAnchor" id="H23"><span class="h2">Choice of drug</span><span class="headingEndMark"> — </span>Data comparing antihypertensive drugs in children are lacking and hence it is not possible to make an evidence-based choice [<a href="#rid23">23</a>]. Therefore, the recommendations on the choice of agent for initial therapy are based upon the underlying cause of HTN, concurrent disorders, and the preference and experience of the responsible clinician [<a href="#rid24">24,25</a>]. Data from adult trials and limited pediatric information have provided information regarding the choice of antihypertensive drugs for children with a specific underlying medical condition, such as primary HTN, CKD, and diabetes mellitus (DM). (See  <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p class="headingAnchor" id="H24"><span class="h3">Primary hypertension</span><span class="headingEndMark"> — </span>In children, there has not been a consensus on the best initial pharmacologic agent to treat primary HTN. The 2017 AAP guidelines suggest that pharmacologic therapy be initiated with one of the following classes: thiazide diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or calcium channel blockers (CCBs)  (<a class="graphic graphic_table graphicRef71466" href="/z/d/graphic/71466.html" rel="external">table 5</a>) [<a href="#rid1">1</a>]. In our practice, we typically start with an agent that blocks the renin/angiotensin system (ie, ACE inhibitor or ARB) or a CCB for adolescent females who are sexually active and are unlikely to follow appropriate counseling on contraception. Patients on ACE/ARB need ongoing monitoring for changes in serum creatinine and potassium, particularly after medication initiation or significant dose increases. (See <a class="local">'Antihypertensive drugs'</a> below.)</p><p>Clinical short-term trials have shown that ACE inhibitors and CCBs are effective, safe, and well tolerated in children, but these two classes of drugs are more expensive than thiazide diuretics. However, diuretic therapy is associated with metabolic complications (eg, hypokalemia, glucose intolerance, weight gain, adverse lipid effects) and the need for periodic blood chemistry monitoring [<a href="#rid26">26</a>]. In addition, thiazide diuretics may alter glucose metabolism, which may be an important concern for children who are overweight or obese who are at risk for developing type 2 DM [<a href="#rid27">27</a>]. (See <a class="local">'Thiazide diuretics'</a> below.)</p><p>As a result, the use of ACE inhibitors, ARBs, or CCBs has been advocated as the initial therapy for primary HTN, particularly in children who are overweight or obese. However, thiazide diuretics are a reasonable alternative for patients who are compliant with medication and dietary sodium restriction, and have no evidence of hyperglycemia, hyperlipidemia, or hyperuricemia.</p><p>If the target BP goal is not met with the maximum allowable dose of the initial medication (ACE inhibitor, ARB, or CCB), we add a thiazide diuretic as a second agent, since salt and water retention commonly occur with antihypertensive therapy [<a href="#rid1">1</a>]. Other alternative approaches include switching agents between drug classes or the use of a beta blocker.</p><p>Data on the initial use of combination therapy of thiazide diuretics and other classes of antihypertensive medications (beta blockers, ACE inhibitors, and CCBs) are limited in children with primary HTN, and it is not recommended. (See  <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p class="headingAnchor" id="H459065252"><span class="h3">Secondary hypertension</span></p><p class="headingAnchor" id="H862243766"><span class="h4">Renovascular disease</span><span class="headingEndMark"> — </span>In children with renovascular disease, we use CCBs rather than an ACE inhibitor or ARB because of the concern that ACE inhibitors and ARBs reduce glomerular filtration rate (GFR) and may cause renal function impairment and hyperkalemia. However, the use of ACE/ARB is not contraindicated in unilateral RAS as long as there is appropriate monitoring of renal function and serum potassium and follow-up for adjustment of medication if there is evidence of renal impairment or an increase in potassium level.</p><p>In some cases, endovascular or surgical intervention is warranted, especially for those patients who fail to respond to antihypertensive medications [<a href="#rid28">28</a>].</p><p class="headingAnchor" id="H25"><span class="h4">Chronic kidney disease</span><span class="headingEndMark"> — </span>Studies on the use of ACE inhibitors in children are limited, but are consistent with the adult data demonstrating their benefit in delaying progression of renal insufficiency. ACE inhibitor or ARB therapy appears most beneficial in patients with renal disease associated with proteinuria and should be used as the initial therapy in these patients [<a href="#rid1">1,29,30</a>]. (See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a>.)</p><p>However, ACE inhibitors or ARBs reduce GFR, so close monitoring for possible increases in creatinine and potassium is needed. A more complete discussion on treatment of HTN in children with CKD is discussed separately. (See <a class="local">'ACE inhibitors'</a> below and <a class="local">'ARBs'</a> below and  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Hypertension'</a>.)</p><p class="headingAnchor" id="H26"><span class="h4">Diabetes mellitus</span><span class="headingEndMark"> — </span>Limited studies in children with type 1 diabetic nephropathy are consistent with data from randomized controlled trials in adults that demonstrate ACE inhibitors and ARBs delay the progression of diabetic nephropathy and decrease albuminuria in both type 1 and type 2 diabetes [<a href="#rid29">29</a>]. Thus, ACE inhibitors, or, if not tolerated, ARBs, are the preferred drugs in children with diabetes because of their potential renoprotective properties. (See  <a class="medical medical_review" href="/z/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/5818.html" rel="external">"Complications and screening in children and adolescents with type 1 diabetes mellitus", section on 'Hypertension'</a> and  <a class="medical medical_review" href="/z/d/html/5826.html" rel="external">"Chronic complications and screening in children and adolescents with type 2 diabetes mellitus", section on 'Hypertension'</a>.)</p><p>HTN in type 2 diabetes is often related to obesity; thus, weight reduction is an important component of HTN therapy in these patients.</p><p class="headingAnchor" id="H1428463702"><span class="h3">Sexually active females</span><span class="headingEndMark"> — </span>ACE inhibitors and ARBs are <strong>contraindicated</strong> in pregnancy because of known adverse effects on the fetus. As a result, in sexually active female patients, we will initiate treatment with a CCB. However, if a sexually active female patient is treated with either an ACE inhibitor or ARB, she should be counseled on its effect on the fetus and the need for immediate reporting of suspected pregnancy. (See  <a class="medical medical_review" href="/z/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Overview of antihypertensive drugs used in pregnancy'</a>.)</p><p class="headingAnchor" id="H702834450"><span class="h2">Follow-up care</span><span class="headingEndMark"> — </span>Continued follow-up is required to monitor the response to pharmacotherapy and to detect any drug-related adverse effect. After initiation of pharmacologic therapy, we generally reassess the BP every 4 to 6 weeks for dose adjustments and the need for a second or third agent [<a href="#rid1">1</a>]. If there is a good response and the target BP is met and no additional changes are needed, the time interval for follow-up is gradually increased to three to six months.</p><p>Children and adolescents who are treated with only nonpharmacologic interventions are monitored at longer intervals every three to six months [<a href="#rid1">1</a>]. These visits assess the success of nonpharmacologic measures and the need to initiate pharmacologic therapy and reinforcing adherence.</p><p>Home monitoring of BP eliminates the "white-coat effect," and is a useful adjunct to office visits [<a href="#rid1">1</a>]. During home monitoring, parents/caregivers are asked to send a log of the readings in a couple of weeks after medication initiation or adjustments. ABPM is used to assess response to therapy when clinic or home monitoring is insufficient to determine treatment effectiveness.</p><p class="headingAnchor" id="H28"><span class="h3">Discontinuation of therapy</span><span class="headingEndMark"> — </span>Gradual discontinuation of therapy is most likely to be effective in children with mild initial HTN who are well controlled on a single drug and who can be maintained on nonpharmacologic therapy, such as weight loss and sodium restriction. This "step-down" approach can be tried in those selected patients who fulfill these criteria. These patients will require ongoing nonpharmacologic therapy and BP monitoring after drug therapy is discontinued.</p><p>Patients with secondary HTN in whom a cause has been identified and corrected may also be able to discontinue medication. However, patients with prolonged secondary HTN as may be the case for those with coarctation of the aorta or renal artery stenosis, may still have elevated BP or develop HTN even after successful repair and require pharmacologic therapy. So clinicians need to be aware of the risk of persistent HTN based on the underlying etiology. (See  <a class="medical medical_review" href="/z/d/html/5784.html" rel="external">"Management of coarctation of the aorta", section on 'Systemic hypertension'</a>.) </p><p class="headingAnchor" id="H1558159"><span class="h2">Sports participation</span><span class="headingEndMark"> — </span>Recommendation on the level of sports participation is typically made based on the degree of BP elevation, as recommended by the 2017 AAP guidelines on pediatric HTN [<a href="#rid1">1</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Children with stage 2 HTN should be restricted from high-static sports  (<a class="graphic graphic_figure graphicRef105651" href="/z/d/graphic/105651.html" rel="external">figure 1</a>) even if there is no evidence of end-organ injury. These would include sports classified as IIIA to IIIC in the linked graphic, which categorizes sports based on their cardiovascular (CV) demands. Children with stage 2 HTN, once treated and documented to be normotensive, may be allowed to participate in these sports with ongoing monitoring.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children and adolescents with HTN may participate in competitive sports once evaluation has been completed for hypertensive target organ effects and risks. </p><p></p><p class="headingAnchor" id="H3981711010"><span class="h1">NONPHARMACOLOGIC THERAPY</span></p><p class="headingAnchor" id="H3540992803"><span class="h2">Overview</span><span class="headingEndMark"> — </span>Nonpharmacologic therapy is provided for all children with high blood pressure (BP). In our practice, the following nonpharmacologic measures are used to treat hypertensive children and those with high BP [<a href="#rid1">1,25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Weight reduction for children who are overweight with elevated BP or HTN.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Regular exercise and restriction of sedentary activity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dietary modification, including salt restriction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nonpharmacologic measures to reduce other cardiovascular disease (CVD) risk factors, such as preventing or treating dyslipidemia and avoiding smoking, alcohol, caffeine, and energy drinks. (See  <a class="medical medical_review" href="/z/d/html/16975.html" rel="external">"Pediatric prevention of adult cardiovascular disease: Promoting a healthy lifestyle and identifying at-risk children"</a> and  <a class="medical medical_review" href="/z/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management"</a>.)</p><p></p><p>The long-term beneficial effects of these measures were shown in a prospective study of 798 participants that measured BP in children at 9, 12, or 15 years and at follow-up 20 years later [<a href="#rid31">31</a>]. Resolution of elevated BP as adults was observed in approximately 44 percent of participants with elevated childhood BP measurements. Factors associated with resolution of pediatric elevated BP included significant decrease in body mass index (BMI), decrease in alcohol consumption, increase in vegetable consumption, and improved socioeconomic status.</p><p class="headingAnchor" id="H3594802873"><span class="h2">Weight reduction</span><span class="headingEndMark"> — </span>Dietary counseling with a nutritionist can provide customized recommendations to decrease daily caloric intake. Dietary modification should be coupled with a decrease in time spent on sedentary activities and initiation of a regular exercise regimen. In some cases, referral to pediatric obesity centers for appropriate dietary, pharmacologic, and/or surgical therapy may be warranted. (See  <a class="medical medical_review" href="/z/d/html/5861.html" rel="external">"Clinical evaluation of the child or adolescent with obesity"</a>.)</p><p>Although data in children are not as robust as in adults, several studies and a systemic review of the literature have reported weight reduction was associated with lower BP values in hypertensive children [<a href="#rid32">32-37</a>]. A 2014 systematic review showed obesity intervention regimens modestly reduced BP with a mean decrease of 1.64 mmHg (95% CI -2.56 to -0.71) in systolic BP (SBP) and 1.44 mmHg (95% CI -2.28 to -0.60) in diastolic BP (DBP), which is similar to results seen in adults [<a href="#rid37">37</a>]. In this review, interventions that combined diet and physical activity were more effective in lowering BP than diet or physical activity alone. (See  <a class="medical medical_review" href="/z/d/html/3875.html" rel="external">"Overweight, obesity, and weight reduction in hypertension"</a>.)</p><p class="headingAnchor" id="H1511173591"><span class="h2">Exercise</span><span class="headingEndMark"> — </span>Exercise lowers BP, decreases the risk of atherosclerosis and CVD, and prevents and treats metabolic syndrome [<a href="#rid33">33,38-43</a>]. Children should be instructed to participate in moderate to vigorous aerobic activity in 30- to 60-minute sessions for at least three to five days per week. An expert panel sponsored by the United States National Heart, Lung, and Blood Institute (NHLBI) has developed age-based recommendations for daily physical activity for children  (<a class="graphic graphic_table graphicRef75748" href="/z/d/graphic/75748.html" rel="external">table 6</a>).</p><p>Data has shown short-term physical activity leads to a small but not significant reduction of BP [<a href="#rid42">42</a>]. However, it appears that sustained regular physical activity is effective in lowering BP, and the more vigorous the activity the greater the impact on reducing BP [<a href="#rid38">38,44</a>].</p><p>As cited above, the antihypertensive effect of physical activity combined with weight loss is greater than that with weight loss or exercise alone. However, the combination of weight loss and physical training may not improve the adverse effects of obesity on left ventricular function or size in adolescents [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H3328460258"><span class="h2">Diet</span><span class="headingEndMark"> — </span>There are limited data on the effect of dietary changes upon BP in children. However, it is generally accepted based upon adult trials that a reduction in salt intake and an increased intake of fresh fruits, vegetables, and low-fat dairy products (eg, the Dietary Approaches to Stop Hypertension [DASH] diet [<a href="#rid46">46</a>]) are beneficial in children and adolescents with HTN [<a href="#rid1">1</a>].</p><p class="headingAnchor" id="H840358126"><span class="h3">Salt restriction</span><span class="headingEndMark"> — </span>The benefit of salt restriction for children with HTN is based on indirect data from well-controlled trials in adults and observational pediatric data [<a href="#rid34">34,47-49</a>]. In particular, there appears to be a greater benefit in salt restriction for Black individuals and patients with established HTN or renal insufficiency. Based on the available evidence, the 2017 AAP guidelines recommend that dietary sodium be restricted to &lt;2300 mg/day. In younger children, the normal requirement of sodium is between 2 to 3 mEq/kg per day. (See  <a class="medical medical_review" href="/z/d/html/3877.html" rel="external">"Salt intake and hypertension"</a>.)</p><p>In our practice, we begin dietary salt modification with a no-added-salt diet. This also includes a reduction in or elimination of foods containing large amounts of salt (eg, potato chips, pretzels, processed foods). Parents and caregivers are encouraged to read food package labels to determine the sodium content of prepared foods and avoid those with high salt content. In addition, lunches provided by school programs need to be evaluated to ensure avoiding foods with high salt content. (See  <a class="medical medical_patient" href="/z/d/html/4411.html" rel="external">"Patient education: Low-sodium diet (Beyond the Basics)"</a>.)</p><p class="headingAnchor" id="H325947792"><span class="h3">Energy drinks</span><span class="headingEndMark"> — </span>Energy drinks may contain a high amount of sugar, caffeine, and other stimulants. They can cause excessive weight gain and increase in blood pressure or worsening of blood pressure in those with elevated BP or hypertension [<a href="#rid50">50,51</a>]. As a result, they should be avoided in children with elevated BP. </p><p class="headingAnchor" id="H3679068580"><span class="h3">Potassium intake and the DASH diet</span><span class="headingEndMark"> — </span>Pediatric data from observational studies and clinical trials in adolescents have shown that diets rich in fresh vegetables and fruits, reduced fat (whole grains, low-fat milk products, fish and poultry), and reduced sodium (eg, the Dietary Approaches to Stop Hypertension [DASH] diet) are associated with reducing elevated BP [<a href="#rid52">52-56</a>]. As a result, a diet such as the DASH diet with a high intake of potassium and low intake of fat and sodium is recommended for children with high BP  (<a class="graphic graphic_table graphicRef64935" href="/z/d/graphic/64935.html" rel="external">table 7</a>) [<a href="#rid1">1</a>]. (See  <a class="medical medical_review" href="/z/d/html/3878.html" rel="external">"Diet in the treatment and prevention of hypertension", section on 'Our approach: Comprehensive dietary modification'</a>.)</p><p class="headingAnchor" id="H1381981190"><span class="h2">Avoidance of excess alcohol</span><span class="headingEndMark"> — </span>Multiple studies in adults have shown a clear association between excess alcohol intake and the development of HTN. The applicability of these findings to children has not been well studied. Nevertheless, excess alcohol intake should be avoided to improve weight loss, BP control, and other health concerns. (See  <a class="medical medical_review" href="/z/d/html/2784.html" rel="external">"Cardiovascular benefits and risks of moderate alcohol consumption"</a>.)</p><p class="headingAnchor" id="H2124414012"><span class="h2">Smoking</span><span class="headingEndMark"> — </span>In hypertensive children and adolescents, smoking and exposure to tobacco smoke should be avoided because it increases the risk of CVD, as well as lung cancer. (See  <a class="medical medical_review" href="/z/d/html/3866.html" rel="external">"Smoking and hypertension"</a> and  <a class="medical medical_review" href="/z/d/html/6375.html" rel="external">"Secondhand smoke exposure: Effects in children", section on 'Cardiovascular disease'</a>.)</p><p class="headingAnchor" id="H2346429777"><span class="h2">Dyslipidemia</span><span class="headingEndMark"> — </span>Dietary measures should be initiated in children with dyslipidemia, another CVD risk factor, which is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/17048.html" rel="external">"Dyslipidemia in children and adolescents: Management", section on 'Dietary modification'</a>.)</p><p class="headingAnchor" id="H3379649139"><span class="h1">ANTIHYPERTENSIVE DRUGS</span></p><p class="headingAnchor" id="H3031984089"><span class="h2">Overview</span><span class="headingEndMark"> — </span>The following sections describes the antihypertensive drugs used in the treatment of pediatric HTN. The initial choice of antihypertensive agent is discussed in the section on management approach. (See <a class="local">'Choice of drug'</a> above.)</p><p>The number of antihypertensive drugs in children that have been systematically studied has increased due to the 1997 US Food and Drug Administration Modernization Act (FDAMA) and the 2002 Best Pharmaceuticals for Children Act (BPCA). As a result, efficacy and safety evaluation are available for antihypertensive medications that have been introduced subsequently. However, the legislation did not affect older commonly used drugs whose patent protection had expired. As a result, data are sparse on the effects of different older classes of antihypertensive medications in children [<a href="#rid57">57</a>]. In addition, most trials are of variable quality, funded by pharmaceutical companies, of short duration, and typically have outcome measures that are limited to lowering BP and not end-organ damage.</p><p>The 2017 AAP high BP guidelines includes dosing recommendations for antihypertensive drugs  (<a class="graphic graphic_table graphicRef71466" href="/z/d/graphic/71466.html" rel="external">table 5</a>) [<a href="#rid1">1</a>]. These recommendations were based upon data from industry-sponsored clinical trials and single-center observational studies. When data were not available, recommendations were based on collective clinical experience and consensus opinions from experts in the field.</p><p>The following sections describes the antihypertensive drugs used in the treatment of pediatric HTN. The initial choice of antihypertensive agent is discussed in the section on management approach. (See <a class="local">'Choice of drug'</a> above.)</p><p class="headingAnchor" id="H1991674629"><span class="h2">ACE inhibitors</span><span class="headingEndMark"> — </span>Angiotensin-converting enzyme (ACE) inhibitors (eg, <a class="drug drug_pediatric" data-topicid="13112" href="/z/d/drug information/13112.html" rel="external">captopril</a>, <a class="drug drug_pediatric" data-topicid="83360" href="/z/d/drug information/83360.html" rel="external">enalapril</a>, <a class="drug drug_pediatric" data-topicid="12558" href="/z/d/drug information/12558.html" rel="external">lisinopril</a>, and <a class="drug drug_pediatric" data-topicid="13014" href="/z/d/drug information/13014.html" rel="external">fosinopril</a>) are well tolerated and widely used in hypertensive children. They inhibit the production of angiotensin II by blocking the ACE. In children, efficacy and dosing data are available for enalapril, lisinopril, <a class="drug drug_pediatric" data-topicid="12871" href="/z/d/drug information/12871.html" rel="external">benazepril</a>, and fosinopril.</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13112" href="/z/d/drug information/13112.html" rel="external">Captopril</a> was the first available ACE inhibitor used in pediatrics, but it has been supplanted by longer acting ACE inhibitors. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="83360" href="/z/d/drug information/83360.html" rel="external">Enalapril</a> has received US Food and Drug Administration (FDA) approval as an antihypertensive drug for children following completion of both a pharmacokinetic and a dose-dependent trial. The former demonstrated similar pharmacokinetics in infants and children when compared with adults [<a href="#rid58">58</a>], while the latter demonstrated a dose-dependent response with a low incidence of side effects [<a href="#rid59">59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12558" href="/z/d/drug information/12558.html" rel="external">Lisinopril</a> is effective and safe [<a href="#rid60">60</a>]. Based upon a dose that ranged between 0.1 and 0.2 mg/kg, pharmacokinetics of lisinopril in children were similar to those reported in adults with a peak serum concentration between five and six hours after administration [<a href="#rid61">61</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13014" href="/z/d/drug information/13014.html" rel="external">Fosinopril</a> has been shown to reduce BP in children [<a href="#rid62">62</a>], although dosing recommendations are limited to children greater than 50 kg. There appear to be differences in dose response based upon ethnicity. Black children appear to require a higher dose per body weight to achieve similar BP reduction compared with other children (ie, White, Asian, and Hispanic children) [<a href="#rid63">63</a>].</p><p></p><p>Studies in adults suggest that the antihypertensive effect of ACE inhibitors is increased by concurrent salt restriction [<a href="#rid64">64</a>]. Salt restriction increases renin release, making the BP more angiotensin II-dependent and therefore more responsive to therapy with an ACE inhibitors. (See  <a class="medical medical_review" href="/z/d/html/3815.html" rel="external">"Renin-angiotensin system inhibition in the treatment of hypertension"</a>.)</p><p class="headingAnchor" id="H4195782348"><span class="h2">ARBs</span><span class="headingEndMark"> — </span>Angiotensin-receptor blockers (ARBs) block the binding of angiotensin II to the AT1 receptor. ARBs used in children include <a class="drug drug_pediatric" data-topicid="17058" href="/z/d/drug information/17058.html" rel="external">candesartan</a>, <a class="drug drug_pediatric" data-topicid="13019" href="/z/d/drug information/13019.html" rel="external">irbesartan</a>, <a class="drug drug_pediatric" data-topicid="13047" href="/z/d/drug information/13047.html" rel="external">losartan</a>, <a class="drug drug_pediatric" data-topicid="16034" href="/z/d/drug information/16034.html" rel="external">olmesartan</a>, and <a class="drug drug_pediatric" data-topicid="13078" href="/z/d/drug information/13078.html" rel="external">valsartan</a>, which have been FDA approved [<a href="#rid57">57,65-70</a>]. However, in a larger efficacy study, irbesartan failed to show a beneficial effect in hypertensive children between 6 and 16 years of age. As a result, irbesartan is <strong>not</strong> recommended as a pediatric antihypertensive agent [<a href="#rid71">71</a>]. A review of the literature reported that ARBs were effective and safe in lowering BP and proteinuria in children [<a href="#rid72">72</a>].</p><p>ARBs are a good alternative if there are significant side effects (eg, cough) associated with the use of an ACE inhibitor. However, the use of both is not recommended based on multiple studies in adult patients that demonstrated an increased risk of adverse effects (eg, hypotension, syncope, worsening of renal function, and hyperkalemia). (See  <a class="medical medical_review" href="/z/d/html/3816.html" rel="external">"Major side effects of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers", section on 'Combination of ACE inhibitors and ARBs'</a>.)</p><p class="headingAnchor" id="H375892729"><span class="h2">Thiazide diuretics</span><span class="headingEndMark"> — </span>There is an extensive clinical experience but limited published efficacy data regarding the use of thiazide diuretics in children [<a href="#rid73">73</a>]. Thiazide diuretics may be used as an initial agent or as a second agent, when needed, as it enhances the effect of many other antihypertensive drugs (eg, ACE inhibitors, ARBs, and beta blockers) when given as combination therapy [<a href="#rid74">74,75</a>]. Optimal efficacy of thiazides, given alone or in combination with other drugs, requires concurrent salt restriction [<a href="#rid76">76,77</a>]. However, thiazide diuretics are associated with several adverse effects including hypokalemia, hyponatremia, hyperuricemia, hyperglycemia, hyperlipidemia, hypomagnesemia, and an increased incidence of type 2 diabetes mellitus, so ongoing monitoring of laboratory tests is needed. (See  <a class="medical medical_review" href="/z/d/html/3877.html" rel="external">"Salt intake and hypertension"</a> and  <a class="medical medical_review" href="/z/d/html/3860.html" rel="external">"Use of thiazide diuretics in patients with primary (essential) hypertension", section on 'Side effects'</a>.)</p><p class="headingAnchor" id="H840902861"><span class="h2">Calcium channel blockers</span><span class="headingEndMark"> — </span>Increasing experience with long-acting CCBs (such as extended-release <a class="drug drug_pediatric" data-topicid="12643" href="/z/d/drug information/12643.html" rel="external">nifedipine</a> and <a class="drug drug_pediatric" data-topicid="12603" href="/z/d/drug information/12603.html" rel="external">amlodipine</a>) demonstrates their efficacy and safety in children with HTN, particularly primary HTN [<a href="#rid78">78-82</a>]. However, a randomized, placebo-controlled three-week trial of extended release <a class="drug drug_pediatric" data-topicid="86263" href="/z/d/drug information/86263.html" rel="external">felodipine</a> failed to show a fall in systolic BP (SBP) greater than placebo at any dose in 133 children with primary HTN [<a href="#rid83">83</a>].</p><p>A limitation of long-acting CCBs is the minimum dose formulation that is currently available, resulting in a range of mean daily dose from 0.06 to 0.23 mg/kg per day [<a href="#rid78">78,80</a>]. Thus, smaller children who received a larger dose of medication per body weight may be more likely to experience dose-related adverse effects. (See  <a class="medical medical_review" href="/z/d/html/3832.html" rel="external">"Major side effects and safety of calcium channel blockers"</a>.)</p><p>CCBs are contraindicated in patients with sinus node dysfunction (see  <a class="medical medical_review" href="/z/d/html/1072.html" rel="external">"Sinus node dysfunction: Treatment"</a>), but is the preferred class of antihypertensive agents in patients with HTN and diminished renal function or hyperkalemia or sexually active females who are unlikely to follow appropriate counseling on contraception.</p><p>The use of short-acting <a class="drug drug_pediatric" data-topicid="12643" href="/z/d/drug information/12643.html" rel="external">nifedipine</a> is not recommended in hypertensive children given concerns about its safety and the inability to accurately administer small doses [<a href="#rid84">84</a>].</p><p class="headingAnchor" id="H3528739999"><span class="h2">Beta blockers</span><span class="headingEndMark"> — </span>Beta blockers were among the first and most widely used antihypertensive drugs in children. However, beta blockers are not recommended as initial therapy in children because of the expanded adverse outcomes associated with beta blockers (eg, impaired glucose tolerance and interference in lipid metabolism) and is less effective than other antihypertensive agents in preventing stroke in adults with primary hypertension. In addition, beta blockers can cause increased bronchial obstruction and airway reactivity in children with asthma. Beta blockers may be used as second or third agents for patients who fail to respond to initial monotherapy. (See  <a class="medical medical_review" href="/z/d/html/967.html" rel="external">"Major side effects of beta blockers"</a> and  <a class="medical medical_review" href="/z/d/html/3831.html" rel="external">"Treatment of hypertension in asthma and COPD", section on 'Beta blockers'</a> and  <a class="medical medical_review" href="/z/d/html/3869.html" rel="external">"Choice of drug therapy in primary (essential) hypertension"</a>.)</p><p>Most of the original studies in children were performed with <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">propranolol</a>, which has been largely replaced by better tolerated, longer-acting, and more selective drugs such as <a class="drug drug_pediatric" data-topicid="12848" href="/z/d/drug information/12848.html" rel="external">atenolol</a>, <a class="drug drug_pediatric" data-topicid="12605" href="/z/d/drug information/12605.html" rel="external">metoprolol</a>, and <a class="drug drug_general" data-topicid="9158" href="/z/d/drug information/9158.html" rel="external">bisoprolol</a>. Both bisoprolol and metoprolol have been shown to be effective in reducing BP in children [<a href="#rid57">57</a>]. These agents are available in combination with <a class="drug drug_pediatric" data-topicid="13357" href="/z/d/drug information/13357.html" rel="external">hydrochlorothiazide</a>. <a class="drug drug_pediatric" data-topicid="13403" href="/z/d/drug information/13403.html" rel="external">Labetalol</a> is another beta blocker agent, which also has alpha blocking activity [<a href="#rid74">74,85,86</a>]. <a class="drug drug_pediatric" data-topicid="13279" href="/z/d/drug information/13279.html" rel="external">Esmolol</a> is an intravenous beta blocker agent, primarily used to treat postoperative or intraoperative tachycardia and HTN [<a href="#rid87">87</a>].</p><p class="headingAnchor" id="H71168716"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109575.html" rel="external">"Society guideline links: Hypertension in children"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15659.html" rel="external">"Patient education: High blood pressure in children (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/1190.html" rel="external">"Patient education: High blood pressure in children (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/1184.html" rel="external">"Patient education: High blood pressure treatment in children (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H30"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Treatment for chronic hypertension (HTN) includes both nonpharmacologic and pharmacologic interventions. Management decisions are dependent upon the severity of HTN  (<a class="graphic graphic_table graphicRef114574" href="/z/d/graphic/114574.html" rel="external">table 1</a>), the underlying cause, the presence of other cardiovascular disease (CVD) risk factors, and defining target blood pressure (BP) goals, which are consistent with the American Academy of Pediatrics (AAP) guidelines. (See <a class="local">'Management approach'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Target BP goal</strong> – In our practice, for children diagnosed with HTN and treated with nonpharmacologic and/or pharmacologic therapy, the target BP goal is a reduction of systolic and diastolic BP below the 90<sup>th</sup> percentile or &lt;130/80 in adolescents (13 years or older). A lower goal is used for children who have CKD. (See <a class="local">'Target blood pressure goals'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonpharmacologic therapy</strong> – Nonpharmacologic therapy is provided for <strong>all children with elevated BP and any stage of HTN</strong>. This consists of weight reduction for children who are overweight, regular exercise  (<a class="graphic graphic_table graphicRef75748" href="/z/d/graphic/75748.html" rel="external">table 6</a>), restriction of sedentary activity, dietary salt restriction, and prevention of other CVD risk factors (eg, dyslipidemia and smoking). (See <a class="local">'Nonpharmacologic therapy'</a> above and <a class="local">'Who should be treated'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pharmacologic therapy</strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For <strong>children with elevated BP</strong>, we suggest <strong>not</strong> to initially administer pharmacologic therapy and only continue nonpharmacologic therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For <strong>asymptomatic children with stage 1 HTN</strong>, we suggest <strong>not</strong> to initially administer pharmacologic therapy and continue only to provide nonpharmacologic therapy to lower BP to target goals (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Pharmacologic therapy is considered if BP target goals are not met after six months of nonpharmacologic therapy. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For <strong>children with stage 1 HTN who are symptomatic or have evidence of end-organ target damage</strong> (eg, left ventricular hypertrophy), we suggest administering pharmacologic therapy in addition to nonpharmacologic therapy versus only nonpharmacologic therapy to reach target BP goals (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For <strong>children with stage 2 HTN</strong>, management includes both pharmacologic and nonpharmacologic therapy. Children with neurologic symptoms should be evaluated and treated emergently. (See  <a class="medical medical_review" href="/z/d/html/6111.html" rel="external">"Epidemiology, risk factors, and etiology of hypertension in children and adolescents", section on 'Secondary hypertension'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For <strong>children with CKD</strong>, both nonpharmacologic and pharmacologic therapy is provided for any child with elevated BP or HTN. (See  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Hypertension'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For <strong>children with</strong> <strong>diabetes mellitus</strong> (DM), both nonpharmacologic and pharmacologic therapy is provided for any child with any stage of HTN. (See  <a class="medical medical_review" href="/z/d/html/5826.html" rel="external">"Chronic complications and screening in children and adolescents with type 2 diabetes mellitus", section on 'Hypertension'</a> and  <a class="medical medical_review" href="/z/d/html/5818.html" rel="external">"Complications and screening in children and adolescents with type 1 diabetes mellitus", section on 'Hypertension'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Choice of antihypertensive agent</strong> – Data comparing antihypertensive drugs in children are lacking and hence it is not possible to make an evidence-based choice. Recommendations on the choice of agent for initial therapy are based upon the underlying cause of HTN, concurrent disorders, and the preference and experience of the responsible clinician. (See <a class="local">'Antihypertensive drugs'</a> above.)</p><p></p><p class="bulletIndent2">In general, a single agent is first administered and a second agent from a different class is only added when initial drug dose reaches the highest recommended level or if the patient begins to experience side effects from the initial drug. Thiazide diuretic is the most commonly used second antihypertensive agent. (See <a class="local">'General principles when starting pharmacologic therapy'</a> above.)</p><p></p><p class="bulletIndent2">In our practice, the following classes of antihypertensive agents are used initially based on the clinical context. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Primary hypertension</strong> – Angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or calcium channel blockers (CCBs). (See <a class="local">'Primary hypertension'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Renal vascular disease</strong> – CCB rather than ACE inhibitor or ARB because of concerns of a reduction in glomerular filtration rate with ACE inhibitors and ARBs. (See <a class="local">'Renovascular disease'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Chronic kidney disease</strong> – ACE inhibitor or ARB as data suggest that these agents slow the progression of CKD but close monitoring of kidney function is required. (See  <a class="medical medical_review" href="/z/d/html/7169.html" rel="external">"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults"</a> and <a class="local">'ACE inhibitors'</a> above and <a class="local">'ARBs'</a> above and  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Hypertension'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Diabetes mellitus</strong> – ACE inhibitor or ARB as data suggest that these agents slow the progression of diabetic nephropathy. (See  <a class="medical medical_review" href="/z/d/html/3052.html" rel="external">"Treatment of diabetic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/5818.html" rel="external">"Complications and screening in children and adolescents with type 1 diabetes mellitus", section on 'Hypertension'</a> and  <a class="medical medical_review" href="/z/d/html/5826.html" rel="external">"Chronic complications and screening in children and adolescents with type 2 diabetes mellitus", section on 'Hypertension'</a>.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Sexually active females</strong> – CCB as ACE inhibitors and ARBs are <strong>contraindicated</strong> in pregnancy because of known teratogenic adverse effects. (See  <a class="medical medical_review" href="/z/d/html/4789.html" rel="external">"Adverse effects of angiotensin converting enzyme inhibitors and receptor blockers in pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/6815.html" rel="external">"Treatment of hypertension in pregnant and postpartum patients", section on 'Overview of antihypertensive drugs used in pregnancy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – Continued follow-up is required to monitor the response to pharmacotherapy, detect any drug-related adverse effect and make dosing changes or introduce additional agents to achieve target BP goal. (See <a class="local">'Follow-up care'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sports participation</strong> – The level of sports participation is based on the degree of BP elevation and evidence of end-organ damage. (See <a class="local">'Sports participation'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Flynn JT, Kaelber DC, Baker-Smith CM, et al. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics 2017; 140.</a></li><li><a class="nounderline abstract_t">Thompson M, Dana T, Bougatsos C, et al. Screening for hypertension in children and adolescents to prevent cardiovascular disease. Pediatrics 2013; 131:490.</a></li><li><a class="nounderline abstract_t">Yang L, Magnussen CG, Yang L, et al. Elevated Blood Pressure in Childhood or Adolescence and Cardiovascular Outcomes in Adulthood: A Systematic Review. Hypertension 2020; 75:948.</a></li><li><a class="nounderline abstract_t">Leiba A, Twig G, Levine H, et al. Hypertension in late adolescence and cardiovascular mortality in midlife: a cohort study of 2.3 million 16- to 19-year-old examinees. Pediatr Nephrol 2016; 31:485.</a></li><li><a class="nounderline abstract_t">Li S, Chen W, Srinivasan SR, Berenson GS. Childhood blood pressure as a predictor of arterial stiffness in young adults: the bogalusa heart study. Hypertension 2004; 43:541.</a></li><li><a class="nounderline abstract_t">Aatola H, Magnussen CG, Koivistoinen T, et al. Simplified definitions of elevated pediatric blood pressure and high adult arterial stiffness. Pediatrics 2013; 132:e70.</a></li><li><a class="nounderline abstract_t">Mahoney LT, Burns TL, Stanford W, et al. Coronary risk factors measured in childhood and young adult life are associated with coronary artery calcification in young adults: the Muscatine Study. J Am Coll Cardiol 1996; 27:277.</a></li><li><a class="nounderline abstract_t">Davis PH, Dawson JD, Mahoney LT, Lauer RM. Increased carotid intimal-medial thickness and coronary calcification are related in young and middle-aged adults. The Muscatine study. Circulation 1999; 100:838.</a></li><li><a class="nounderline abstract_t">Juhola J, Magnussen CG, Berenson GS, et al. Combined effects of child and adult elevated blood pressure on subclinical atherosclerosis: the International Childhood Cardiovascular Cohort Consortium. Circulation 2013; 128:217.</a></li><li><a class="nounderline abstract_t">Raitakari OT, Juonala M, Taittonen L, et al. Pulse pressure in youth and carotid intima-media thickness in adulthood: the cardiovascular risk in young Finns study. Stroke 2009; 40:1519.</a></li><li><a class="nounderline abstract_t">Sorof JM, Alexandrov AV, Cardwell G, Portman RJ. Carotid artery intimal-medial thickness and left ventricular hypertrophy in children with elevated blood pressure. Pediatrics 2003; 111:61.</a></li><li><a class="nounderline abstract_t">Daniels SR, Witt SA, Glascock B, et al. Left atrial size in children with hypertension: the influence of obesity, blood pressure, and left ventricular mass. J Pediatr 2002; 141:186.</a></li><li><a class="nounderline abstract_t">Daniels SR, Loggie JM, Khoury P, Kimball TR. Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. Circulation 1998; 97:1907.</a></li><li><a class="nounderline abstract_t">Toprak A, Wang H, Chen W, et al. Relation of childhood risk factors to left ventricular hypertrophy (eccentric or concentric) in relatively young adulthood (from the Bogalusa Heart Study). Am J Cardiol 2008; 101:1621.</a></li><li><a class="nounderline abstract_t">Zhang H, Zhang T, Li S, et al. Long-Term Excessive Body Weight and Adult Left Ventricular Hypertrophy Are Linked Through Later-Life Body Size and Blood Pressure: The Bogalusa Heart Study. Circ Res 2017; 120:1614.</a></li><li><a class="nounderline abstract_t">Zhang T, Li S, Bazzano L, et al. Trajectories of Childhood Blood Pressure and Adult Left Ventricular Hypertrophy: The Bogalusa Heart Study. Hypertension 2018; 72:93.</a></li><li><a class="nounderline abstract_t">Litwin M, Niemirska A, Sladowska-Kozlowska J, et al. Regression of target organ damage in children and adolescents with primary hypertension. Pediatr Nephrol 2010; 25:2489.</a></li><li><a class="nounderline abstract_t">Seeman T, Gilík J, Vondrák K, et al. Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy. Am J Hypertens 2007; 20:990.</a></li><li><a class="nounderline abstract_t">Seeman T, Dostálek L, Gilík J. Control of hypertension in treated children and its association with target organ damage. Am J Hypertens 2012; 25:389.</a></li><li><a class="nounderline abstract_t">Matteucci MC, Chinali M, Rinelli G, et al. Change in cardiac geometry and function in CKD children during strict BP control: a randomized study. Clin J Am Soc Nephrol 2013; 8:203.</a></li><li><a class="nounderline abstract_t">Kupferman JC, Aronson Friedman L, Cox C, et al. BP control and left ventricular hypertrophy regression in children with CKD. J Am Soc Nephrol 2014; 25:167.</a></li><li><a class="nounderline abstract_t">Leiba A, Fishman B, Twig G, et al. Association of Adolescent Hypertension With Future End-stage Renal Disease. JAMA Intern Med 2019; 179:517.</a></li><li><a class="nounderline abstract_t">Burrello J, Erhardt EM, Saint-Hilary G, et al. Pharmacological Treatment of Arterial Hypertension in Children and Adolescents: A Network Meta-Analysis. Hypertension 2018; 72:306.</a></li><li><a class="nounderline abstract_t">National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 2004; 114:555.</a></li><li><a class="nounderline abstract_t">Lurbe E, Agabiti-Rosei E, Cruickshank JK, et al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens 2016; 34:1887.</a></li><li class="breakAll">Feld LG, Waz WR. Treatment of hypertension. In: Pediatric Nephrology, Barratt TM, Avner ED, Harmon WE (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 1999. p.63.</li><li><a class="nounderline abstract_t">Ferguson MA, Flynn JT. Rational use of antihypertensive medications in children. Pediatr Nephrol 2014; 29:979.</a></li><li><a class="nounderline abstract_t">Lobeck IN, Alhajjat AM, Dupree P, et al. The management of pediatric renovascular hypertension: a single center experience and review of the literature. J Pediatr Surg 2018; 53:1825.</a></li><li><a class="nounderline abstract_t">Hilgers KF, Dötsch J, Rascher W, Mann JF. Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both? Pediatr Nephrol 2004; 19:956.</a></li><li><a class="nounderline abstract_t">Flynn JT, Mitsnefes M, Pierce C, et al. Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension 2008; 52:631.</a></li><li><a class="nounderline abstract_t">Kelly RK, Thomson R, Smith KJ, et al. Factors Affecting Tracking of Blood Pressure from Childhood to Adulthood: The Childhood Determinants of Adult Health Study. J Pediatr 2015; 167:1422.</a></li><li><a class="nounderline abstract_t">Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. Hypertension 2002; 40:441.</a></li><li><a class="nounderline abstract_t">Rocchini AP, Katch V, Anderson J, et al. Blood pressure in obese adolescents: effect of weight loss. Pediatrics 1988; 82:16.</a></li><li><a class="nounderline abstract_t">Rocchini AP, Key J, Bondie D, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med 1989; 321:580.</a></li><li><a class="nounderline abstract_t">Wabitsch M, Hauner H, Heinze E, et al. Body-fat distribution and changes in the atherogenic risk-factor profile in obese adolescent girls during weight reduction. Am J Clin Nutr 1994; 60:54.</a></li><li><a class="nounderline abstract_t">Holm JC, Gamborg M, Neland M, et al. Longitudinal changes in blood pressure during weight loss and regain of weight in obese boys and girls. J Hypertens 2012; 30:368.</a></li><li><a class="nounderline abstract_t">Cai L, Wu Y, Wilson RF, et al. Effect of childhood obesity prevention programs on blood pressure: a systematic review and meta-analysis. Circulation 2014; 129:1832.</a></li><li><a class="nounderline abstract_t">Hansen HS, Froberg K, Hyldebrandt N, Nielsen JR. A controlled study of eight months of physical training and reduction of blood pressure in children: the Odense schoolchild study. BMJ 1991; 303:682.</a></li><li><a class="nounderline abstract_t">Rocchini AP, Katch V, Schork A, Kelch RP. Insulin and blood pressure during weight loss in obese adolescents. Hypertension 1987; 10:267.</a></li><li><a class="nounderline abstract_t">Kelley GA, Kelley KS, Tran ZV. The effects of exercise on resting blood pressure in children and adolescents: a meta-analysis of randomized controlled trials. Prev Cardiol 2003; 6:8.</a></li><li><a class="nounderline abstract_t">Gidding SS, Barton BA, Dorgan JA, et al. Higher self-reported physical activity is associated with lower systolic blood pressure: the Dietary Intervention Study in Childhood (DISC). Pediatrics 2006; 118:2388.</a></li><li><a class="nounderline abstract_t">Farpour-Lambert NJ, Aggoun Y, Marchand LM, et al. Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children. J Am Coll Cardiol 2009; 54:2396.</a></li><li><a class="nounderline abstract_t">Knowles G, Pallan M, Thomas GN, et al. Physical activity and blood pressure in primary school children: a longitudinal study. Hypertension 2013; 61:70.</a></li><li><a class="nounderline abstract_t">Mark AE, Janssen I. Dose-response relation between physical activity and blood pressure in youth. Med Sci Sports Exerc 2008; 40:1007.</a></li><li><a class="nounderline abstract_t">Mitchell BM, Gutin B, Kapuku G, et al. Left ventricular structure and function in obese adolescents: relations to cardiovascular fitness, percent body fat, and visceral adiposity, and effects of physical training. Pediatrics 2002; 109:E73.</a></li><li><a class="nounderline abstract_t">Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001; 344:3.</a></li><li><a class="nounderline abstract_t">Overwyk KJ, Zhao L, Zhang Z, et al. Trends in Blood Pressure and Usual Dietary Sodium Intake Among Children and Adolescents, National Health and Nutrition Examination Survey 2003 to 2016. Hypertension 2019; 74:260.</a></li><li><a class="nounderline abstract_t">Cooper R, Van Horn L, Liu K, et al. A randomized trial on the effect of decreased dietary sodium intake on blood pressure in adolescents. J Hypertens 1984; 2:361.</a></li><li><a class="nounderline abstract_t">Howe PR, Cobiac L, Smith RM. Lack of effect of short-term changes in sodium intake on blood pressure in adolescent schoolchildren. J Hypertens 1991; 9:181.</a></li><li><a class="nounderline abstract_t">Basrai M, Schweinlin A, Menzel J, et al. Energy Drinks Induce Acute Cardiovascular and Metabolic Changes Pointing to Potential Risks for Young Adults: A Randomized Controlled Trial. J Nutr 2019; 149:441.</a></li><li><a class="nounderline abstract_t">Mansour B, Amarah W, Nasralla E, Elias N. Energy drinks in children and adolescents: demographic data and immediate effects. Eur J Pediatr 2019; 178:649.</a></li><li><a class="nounderline abstract_t">Couch SC, Saelens BE, Khoury PR, et al. Dietary Approaches to Stop Hypertension Dietary Intervention Improves Blood Pressure and Vascular Health in Youth With Elevated Blood Pressure. Hypertension 2021; 77:241.</a></li><li><a class="nounderline abstract_t">Couch SC, Saelens BE, Levin L, et al. The efficacy of a clinic-based behavioral nutrition intervention emphasizing a DASH-type diet for adolescents with elevated blood pressure. J Pediatr 2008; 152:494.</a></li><li><a class="nounderline abstract_t">Moore LL, Bradlee ML, Singer MR, et al. Dietary Approaches to Stop Hypertension (DASH) eating pattern and risk of elevated blood pressure in adolescent girls. Br J Nutr 2012; 108:1678.</a></li><li><a class="nounderline abstract_t">Günther AL, Liese AD, Bell RA, et al. Association between the dietary approaches to hypertension diet and hypertension in youth with diabetes mellitus. Hypertension 2009; 53:6.</a></li><li><a class="nounderline abstract_t">Zafarmand MH, Spanjer M, Nicolaou M, et al. Influence of Dietary Approaches to Stop Hypertension-Type Diet, Known Genetic Variants and Their Interplay on Blood Pressure in Early Childhood: ABCD Study. Hypertension 2020; 75:59.</a></li><li><a class="nounderline abstract_t">Chaturvedi S, Lipszyc DH, Licht C, et al. Pharmacological interventions for hypertension in children. Cochrane Database Syst Rev 2014; :CD008117.</a></li><li><a class="nounderline abstract_t">Shahinfar S, Rippley R, Hogg RJ, et al. Multicenter study of enalapril pharmacokinetics in hypertensive children and infants. Pediatr Res 2000; 47:473A.</a></li><li><a class="nounderline abstract_t">Wells T, Frame V, Soffer B, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension. J Clin Pharmacol 2002; 42:870.</a></li><li><a class="nounderline abstract_t">Soffer B, Zhang Z, Miller K, et al. A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension. Am J Hypertens 2003; 16:795.</a></li><li><a class="nounderline abstract_t">Hogg RJ, Delucchi A, Sakihara G, et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr Nephrol 2007; 22:695.</a></li><li class="breakAll">US Food and Drug Administration. Center for Drug Evaluation and Research. Approved active moieties for which FDA has issued a written request for pediatric studies under Section 3 of the Best Pharmaceuticals for Children Act. Available at: www.fda.gov/cder/foi/esum/2003/19915s037.pdf (Accessed on November 01, 2007).</li><li><a class="nounderline abstract_t">Menon S, Berezny KY, Kilaru R, et al. Racial differences are seen in blood pressure response to fosinopril in hypertensive children. Am Heart J 2006; 152:394.</a></li><li><a class="nounderline abstract_t">MacGregor GA, Markandu ND, Singer DR, et al. Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: a double blind study. Br Med J (Clin Res Ed) 1987; 294:531.</a></li><li><a class="nounderline abstract_t">Sakarcan A, Tenney F, Wilson JT, et al. The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol 2001; 41:742.</a></li><li><a class="nounderline abstract_t">Shahinfar S, Cano F, Soffer BA, et al. A double-blind, dose-response study of losartan in hypertensive children. Am J Hypertens 2005; 18:183.</a></li><li><a class="nounderline abstract_t">Trachtman H, Hainer JW, Sugg J, et al. Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years. J Clin Hypertens (Greenwich) 2008; 10:743.</a></li><li><a class="nounderline abstract_t">Schaefer F, Coppo R, Bagga A, et al. Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age. J Hypertens 2013; 31:993.</a></li><li><a class="nounderline abstract_t">Wells T, Blumer J, Meyers KE, et al. Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension. J Clin Hypertens (Greenwich) 2011; 13:357.</a></li><li><a class="nounderline abstract_t">Hazan L, Hernández Rodriguez OA, Bhorat AE, et al. A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension. Hypertension 2010; 55:1323.</a></li><li><a class="nounderline abstract_t">Flynn JT, Daniels SR. Pharmacologic treatment of hypertension in children and adolescents. J Pediatr 2006; 149:746.</a></li><li><a class="nounderline abstract_t">Herder SD, Weber E, Winkemann A, et al. Efficacy and safety of angiotensin II receptor type 1 antagonists in children and adolescents. Pediatr Nephrol 2010; 25:801.</a></li><li><a class="nounderline abstract_t">Blowey DL. Diuretics in the treatment of hypertension. Pediatr Nephrol 2016; 31:2223.</a></li><li><a class="nounderline abstract_t">Sorof JM, Cargo P, Graepel J, et al. Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial. Pediatr Nephrol 2002; 17:345.</a></li><li><a class="nounderline abstract_t">Berenson GS, Shear CL, Chiang YK, et al. Combined low-dose medication and primary intervention over a 30-month period for sustained high blood pressure in childhood. Am J Med Sci 1990; 299:79.</a></li><li><a class="nounderline abstract_t">Ram CV, Garrett BN, Kaplan NM. Moderate sodium restriction and various diuretics in the treatment of hypertension. Arch Intern Med 1981; 141:1015.</a></li><li><a class="nounderline abstract_t">Singer DR, Markandu ND, Sugden AL, et al. Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide. Hypertension 1991; 17:798.</a></li><li><a class="nounderline abstract_t">Tallian KB, Nahata MC, Turman MA, et al. Efficacy of amlodipine in pediatric patients with hypertension. Pediatr Nephrol 1999; 13:304.</a></li><li><a class="nounderline abstract_t">Flynn JT, Smoyer WE, Bunchman TE. Treatment of hypertensive children with amlodipine. Am J Hypertens 2000; 13:1061.</a></li><li><a class="nounderline abstract_t">Flynn JT, Newburger JW, Daniels SR, et al. A randomized, placebo-controlled trial of amlodipine in children with hypertension. J Pediatr 2004; 145:353.</a></li><li><a class="nounderline abstract_t">Andersen J, Groshong T, Tobias JD. Preliminary experience with amlodipine in the pediatric population. Am J Ther 2006; 13:198.</a></li><li><a class="nounderline abstract_t">Flynn JT. Efficacy and safety of prolonged amlodipine treatment in hypertensive children. Pediatr Nephrol 2005; 20:631.</a></li><li><a class="nounderline abstract_t">Trachtman H, Frank R, Mahan JD, et al. Clinical trial of extended-release felodipine in pediatric essential hypertension. Pediatr Nephrol 2003; 18:548.</a></li><li><a class="nounderline abstract_t">Flynn JT. Safety of short-acting nifedipine in children with severe hypertension. Expert Opin Drug Saf 2003; 2:133.</a></li><li><a class="nounderline abstract_t">Falkner B, Lowenthal DT, Affrime MB. The pharmacodynamic effectiveness of metoprolol in adolescent hypertension. Pediatr Pharmacol (New York) 1982; 2:49.</a></li><li><a class="nounderline abstract_t">Kornbluth A, Frishman WH, Ackerman M. Beta-adrenergic blockade in children. Cardiol Clin 1987; 5:629.</a></li><li class="breakAll">US Food and Drug Administration. Summaries of medical and clinical pharmacology reviews of pediatric studies. Available at: www.fda.gov/cder/pediatric/Summaryreview.htm (Accessed on October 05, 2007).</li></ol></div><div id="topicVersionRevision">Topic 6131 Version 67.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28827377" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23439904" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Screening for hypertension in children and adolescents to prevent cardiovascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32114851" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Elevated Blood Pressure in Childhood or Adolescence and Cardiovascular Outcomes in Adulthood: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26508439" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Hypertension in late adolescence and cardiovascular mortality in midlife: a cohort study of 2.3 million 16- to 19-year-old examinees.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14744922" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Childhood blood pressure as a predictor of arterial stiffness in young adults: the bogalusa heart study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23753088" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Simplified definitions of elevated pediatric blood pressure and high adult arterial stiffness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8557894" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Coronary risk factors measured in childhood and young adult life are associated with coronary artery calcification in young adults: the Muscatine Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10458720" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Increased carotid intimal-medial thickness and coronary calcification are related in young and middle-aged adults. The Muscatine study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23780579" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Combined effects of child and adult elevated blood pressure on subclinical atherosclerosis: the International Childhood Cardiovascular Cohort Consortium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19265060" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pulse pressure in youth and carotid intima-media thickness in adulthood: the cardiovascular risk in young Finns study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12509555" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Carotid artery intimal-medial thickness and left ventricular hypertrophy in children with elevated blood pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12183712" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Left atrial size in children with hypertension: the influence of obesity, blood pressure, and left ventricular mass.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9609083" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18489940" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Relation of childhood risk factors to left ventricular hypertrophy (eccentric or concentric) in relatively young adulthood (from the Bogalusa Heart Study).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28232594" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Long-Term Excessive Body Weight and Adult Left Ventricular Hypertrophy Are Linked Through Later-Life Body Size and Blood Pressure: The Bogalusa Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29785961" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Trajectories of Childhood Blood Pressure and Adult Left Ventricular Hypertrophy: The Bogalusa Heart Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20730452" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Regression of target organ damage in children and adolescents with primary hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17765141" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22089110" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Control of hypertension in treated children and its association with target organ damage.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23124781" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Change in cardiac geometry and function in CKD children during strict BP control: a randomized study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24071004" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : BP control and left ventricular hypertrophy regression in children with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30801616" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Association of Adolescent Hypertension With Future End-stage Renal Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29967035" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pharmacological Treatment of Arterial Hypertension in Children and Adolescents: A Network Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15286277" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467768" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27467768" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23715784" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Rational use of antihypertensive medications in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29397961" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The management of pediatric renovascular hypertension: a single center experience and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15278690" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18725579" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26342719" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Factors Affecting Tracking of Blood Pressure from Childhood to Adulthood: The Childhood Determinants of Adult Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12364344" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Obesity hypertension in children: a problem of epidemic proportions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3288957" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Blood pressure in obese adolescents: effect of weight loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2668763" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8017338" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Body-fat distribution and changes in the atherogenic risk-factor profile in obese adolescent girls during weight reduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22157326" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Longitudinal changes in blood pressure during weight loss and regain of weight in obese boys and girls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24552832" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of childhood obesity prevention programs on blood pressure: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1912915" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : A controlled study of eight months of physical training and reduction of blood pressure in children: the Odense schoolchild study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3305355" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Insulin and blood pressure during weight loss in obese adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12624556" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : The effects of exercise on resting blood pressure in children and adolescents: a meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17142523" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Higher self-reported physical activity is associated with lower systolic blood pressure: the Dietary Intervention Study in Childhood (DISC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20082930" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23150507" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Physical activity and blood pressure in primary school children: a longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18461007" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Dose-response relation between physical activity and blood pressure in youth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11986479" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Left ventricular structure and function in obese adolescents: relations to cardiovascular fitness, percent body fat, and visceral adiposity, and effects of physical training.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136953" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Effects on blood pressure of reduced dietary sodium and the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31230545" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Trends in Blood Pressure and Usual Dietary Sodium Intake Among Children and Adolescents, National Health and Nutrition Examination Survey 2003 to 2016.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6530546" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A randomized trial on the effect of decreased dietary sodium intake on blood pressure in adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1849536" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Lack of effect of short-term changes in sodium intake on blood pressure in adolescent schoolchildren.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30805607" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Energy Drinks Induce Acute Cardiovascular and Metabolic Changes Pointing to Potential Risks for Young Adults: A Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30770983" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Energy drinks in children and adolescents: demographic data and immediate effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33190559" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Dietary Approaches to Stop Hypertension Dietary Intervention Improves Blood Pressure and Vascular Health in Youth With Elevated Blood Pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18346503" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The efficacy of a clinic-based behavioral nutrition intervention emphasizing a DASH-type diet for adolescents with elevated blood pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22243687" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Dietary Approaches to Stop Hypertension (DASH) eating pattern and risk of elevated blood pressure in adolescent girls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19029488" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Association between the dietary approaches to hypertension diet and hypertension in youth with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31786974" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Influence of Dietary Approaches to Stop Hypertension-Type Diet, Known Genetic Variants and Their Interplay on Blood Pressure in Early Childhood: ABCD Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24488616" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Pharmacological interventions for hypertension in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Multicenter study of enalapril pharmacokinetics in hypertensive children and infants</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12162469" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of enalapril for children with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14553956" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A double-blind, placebo-controlled, dose-response study of the effectiveness and safety of lisinopril for children with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17216247" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17216247" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16875928" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Racial differences are seen in blood pressure response to fosinopril in hypertensive children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3103761" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Moderate sodium restriction with angiotensin converting enzyme inhibitor in essential hypertension: a double blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11452706" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The pharmacokinetics of irbesartan in hypertensive children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15752945" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : A double-blind, dose-response study of losartan in hypertensive children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19090875" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Efficacy, safety, and pharmacokinetics of candesartan cilexetil in hypertensive children aged 6 to 17 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23511339" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21545397" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Effectiveness and safety of valsartan in children aged 6 to 16 years with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20385971" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : A double-blind, dose-response study of the efficacy and safety of olmesartan medoxomil in children and adolescents with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17137886" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Pharmacologic treatment of hypertension in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19936798" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Efficacy and safety of angiotensin II receptor type 1 antagonists in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26983630" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Diuretics in the treatment of hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12042891" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Beta-blocker/thiazide combination for treatment of hypertensive children: a randomized double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2301454" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Combined low-dose medication and primary intervention over a 30-month period for sustained high blood pressure in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7247587" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Moderate sodium restriction and various diuretics in the treatment of hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2045142" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Sodium restriction in hypertensive patients treated with a converting enzyme inhibitor and a thiazide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10454779" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Efficacy of amlodipine in pediatric patients with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11041159" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Treatment of hypertensive children with amlodipine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15343191" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : A randomized, placebo-controlled trial of amlodipine in children with hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16772760" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Preliminary experience with amlodipine in the pediatric population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15785942" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Efficacy and safety of prolonged amlodipine treatment in hypertensive children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12700955" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Clinical trial of extended-release felodipine in pediatric essential hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12904113" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Safety of short-acting nifedipine in children with severe hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7110756" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : The pharmacodynamic effectiveness of metoprolol in adolescent hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2900069" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Beta-adrenergic blockade in children.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
